Amiselimod

Drug Profile

Amiselimod

Alternative Names: MT-1303

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Class Propylene glycols; Small molecules
  • Mechanism of Action Immunosuppressants; Sphingosine-1-phosphate receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Crohn's disease; Multiple sclerosis; Plaque psoriasis
  • Phase I Autoimmune disorders; Inflammation; Inflammatory bowel diseases; Systemic lupus erythematosus

Most Recent Events

  • 27 Jan 2017 Mitsubishi Tanabe Pharma terminates licence agreement with Biogen for amiselimod worldwide
  • 26 Oct 2016 Biogen discontinues its development programme for amiselimod for all indications (Biogen form 10-Q, October 2016)
  • 01 Oct 2016 Mitsubishi Tanabe Pharma completes a phase II trial in Crohn's disease in Czech Republic, France, Germany, Hungary, Israel, Italy, Japan, the Netherlands, Poland, Slovakia and Ukraine (NCT02378688)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top